87 related articles for article (PubMed ID: 22936637)
1. Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats.
Vats R; Varanasi KV; Arla R; Veeraraghvan S; Rajak S
Biopharm Drug Dispos; 2012 Nov; 33(8):455-65. PubMed ID: 22936637
[TBL] [Abstract][Full Text] [Related]
2. Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats.
Vats R; Varanasi KV; Arla R; Veeraraghavan S; Rajak S; Murthy AN
J Pharm Pharmacol; 2012 Nov; 64(11):1638-45. PubMed ID: 23058051
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Lau YY; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
[TBL] [Abstract][Full Text] [Related]
4. Effect of ciprofloxacin and grapefruit juice on oral pharmacokinetics of riluzole in Wistar rats.
Ravi PR; Vats R; Kora UR
J Pharm Pharmacol; 2013 Mar; 65(3):337-44. PubMed ID: 23356842
[TBL] [Abstract][Full Text] [Related]
5. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time.
Ryu KH; Han HY; Lee SY; Jeon SD; Im GJ; Lee BY; Kim K; Lim KM; Chung JH
Thromb Res; 2009 Jul; 124(3):328-34. PubMed ID: 19349067
[TBL] [Abstract][Full Text] [Related]
6. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
Cruz-Fernández JM; Bedarida GV; Adgey J; Allen C; Johnson-Levonas AO; Massaad R
Int J Clin Pract; 2005 Jun; 59(6):619-27. PubMed ID: 15924587
[TBL] [Abstract][Full Text] [Related]
9. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems.
Lau YY; Okochi H; Huang Y; Benet LZ
J Pharmacol Exp Ther; 2006 Feb; 316(2):762-71. PubMed ID: 16258024
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of anti-platelet and anti-thrombotic effects of cilostazol with PFA-100® and Multiplate® whole blood aggregometer in vitro, ex vivo and FeCl3-induced thrombosis models in vivo.
Kim CW; Yun JW; Bae IH; Park YH; Jeong YS; Park JW; Chung JH; Park YH; Lim KM
Thromb Res; 2011 Jun; 127(6):565-70. PubMed ID: 21420150
[TBL] [Abstract][Full Text] [Related]
11. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Cilla DD; Whitfield LR; Gibson DM; Sedman AJ; Posvar EL
Clin Pharmacol Ther; 1996 Dec; 60(6):687-95. PubMed ID: 8988072
[TBL] [Abstract][Full Text] [Related]
12. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants.
Shin KH; Yoon G; Yoon IS; Park JW
J Pharm Pharmacol; 2014 Jul; 66(7):961-74. PubMed ID: 24697278
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
[TBL] [Abstract][Full Text] [Related]
15. High-dose supplementation with natural α-tocopherol does neither alter the pharmacodynamics of atorvastatin nor its phase I metabolism in guinea pigs.
Podszun MC; Grebenstein N; Hofmann U; Frank J
Toxicol Appl Pharmacol; 2013 Feb; 266(3):452-8. PubMed ID: 23200775
[TBL] [Abstract][Full Text] [Related]
16. Interaction potential and tolerability of the coadministration of cilostazol and aspirin.
Mallikaarjun S; Forbes WP; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():87-93. PubMed ID: 10702891
[TBL] [Abstract][Full Text] [Related]
17. Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats.
Srinivas M; Annapurna A; Reddy YN
Indian J Exp Biol; 2008 Oct; 46(10):698-703. PubMed ID: 19024167
[TBL] [Abstract][Full Text] [Related]
18. The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leighl N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J
Cancer Chemother Pharmacol; 2012 Feb; 69(2):563-71. PubMed ID: 22057855
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans.
Woo SK; Kang WK; Kwon KI
Clin Pharmacol Ther; 2002 Apr; 71(4):246-52. PubMed ID: 11956507
[TBL] [Abstract][Full Text] [Related]
20. Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats.
Choi DH; Chang KS; Hong SP; Choi JS; Han HK
Biopharm Drug Dispos; 2008 Jan; 29(1):45-50. PubMed ID: 17941000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
